<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299116</url>
  </required_header>
  <id_info>
    <org_study_id>10250</org_study_id>
    <nct_id>NCT01299116</nct_id>
  </id_info>
  <brief_title>Long-Acting Reversible Contraception</brief_title>
  <acronym>LARC</acronym>
  <official_title>Long-Acting Reversible Contraception: New Research to Reduce Unintended Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FHI 360</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the proposed study, women aged 18-29 seeking oral or injectable contraception will be
      offered an opportunity to try LARC instead; the FDA-approved options include two types of
      intrauterine products and one type of subdermal contraceptive implant. Over a 24 month
      period, the experiences of LARC users will be compared to the experiences of those opting for
      their initial short-acting method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this partially randomized patient preference study, women aged 18-29 seeking oral or
      injectable contraception will be offered an opportunity to try LARC instead; the FDA-approved
      options include two types of intrauterine products and one type of subdermal contraceptive
      implant. Over a 24-month period, the experiences of LARC users will be compared to the
      experiences of those opting for their initial short-acting method. It is expected that 38% of
      the participants using short-acting methods will stop using them during the first year and be
      at risk of unintended pregnancy. In contrast, less than 20% of LARC users will want to have
      their contraceptive removed. Continuation rates will be measured and pregnancies will be
      tallied in the two groups to document any differences that emerge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Partially randomized patient preference trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contraceptive Method Discontinuation</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unintended Pregnancy</measure>
    <time_frame>24 months</time_frame>
    <description>Intent-to-treat principles applied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Attitudes to LARC vs SARC</measure>
    <time_frame>24 months</time_frame>
    <description>Level of happiness with initial method (% distribution)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">916</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Preference SARC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants received one of a variety of oral contraceptives or DMPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized LARC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive one of the following interventions:
Implanon® or Nexplanon®; ParaGard®; Mirena®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized SARC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received one of a variety of oral contraceptives or DMPA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMPA</intervention_name>
    <description>Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.</description>
    <arm_group_label>Preference SARC</arm_group_label>
    <arm_group_label>Randomized SARC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral contraceptives</intervention_name>
    <description>Oral contraceptives (any variety of formulations are permitted)</description>
    <arm_group_label>Preference SARC</arm_group_label>
    <arm_group_label>Randomized SARC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Implanon®</intervention_name>
    <description>Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)</description>
    <arm_group_label>Randomized LARC</arm_group_label>
    <other_name>Nexplanon®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ParaGard®</intervention_name>
    <description>Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)</description>
    <arm_group_label>Randomized LARC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirena®</intervention_name>
    <description>Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)</description>
    <arm_group_label>Randomized LARC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 29 years of age;

          -  sexually active;

          -  seeking oral or injectable contraception;

          -  working cell phone;

          -  working email account;

          -  willingness to be contacted by the clinic staff or study coordinators; and,

          -  willingness to complete questionnaires.

        Exclusion Criteria:

          -  currently pregnant;

          -  previous use of a long-acting reversible contraceptive (LARC) method; and,

          -  medical contraindications for oral contraceptives and injectables.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hubacher, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FHI 360</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood Central North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hubacher D, Spector H, Monteith C, Chen PL, Hart C. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial. Am J Obstet Gynecol. 2017 Feb;216(2):101-109. doi: 10.1016/j.ajog.2016.08.033. Epub 2016 Sep 20.</citation>
    <PMID>27662799</PMID>
  </reference>
  <reference>
    <citation>Hubacher D, Spector H, Monteith C, Chen PL, Hart C. Rationale and enrollment results for a partially randomized patient preference trial to compare continuation rates of short-acting and long-acting reversible contraception. Contraception. 2015 Mar;91(3):185-92. doi: 10.1016/j.contraception.2014.11.006. Epub 2014 Nov 15.</citation>
    <PMID>25500324</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <results_first_submitted>November 14, 2017</results_first_submitted>
  <results_first_submitted_qc>January 25, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 26, 2018</results_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AE-adverse event</keyword>
  <keyword>FDA-(U.S.) Food and Drug Administration</keyword>
  <keyword>GCP-Good Clinical Practice guidelines</keyword>
  <keyword>ICH-International Committee on Harmonisation</keyword>
  <keyword>IRB-Institutional Review Board</keyword>
  <keyword>IU-International units</keyword>
  <keyword>mg-milligram(s)</keyword>
  <keyword>mm3-cubic millimeter(s)</keyword>
  <keyword>LARC-Long-Acting reversible contraception</keyword>
  <keyword>PPCNC-Planned Parenthood of North Carolina</keyword>
  <keyword>SAE-serious adverse event</keyword>
  <keyword>SARC-Short-Acting reversible contraception</keyword>
  <keyword>µg-microgram</keyword>
  <keyword>ULN-upper limit of the normal range</keyword>
  <keyword>SubQ-subcutaneous</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This is a partially randomized patient preference trial. Twenty two participants did not contribute data for analysis because they did not start a contraceptive in one of the three groups. For more information see: Hubacher D et al., 2017. The total number going forward for analysis is 894.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SARC - Preference</title>
          <description>Participants received one of a variety of oral contraceptives or DMPA
DMPA: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
oral contraceptives: Oral contraceptives (any variety of formulations are permitted)</description>
        </group>
        <group group_id="P2">
          <title>LARC - Randomized</title>
          <description>Participants receive one of the following interventions:
Implanon® or Nexplanon®; ParaGard®; Mirena®
Implanon®: Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
ParaGard®: Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
Mirena®: Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)</description>
        </group>
        <group group_id="P3">
          <title>SARC - Randomized</title>
          <description>Participants received one of a variety of oral contraceptives or DMPA
DMPA: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="522"/>
                <participants group_id="P2" count="177"/>
                <participants group_id="P3" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="457"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Preference SARC</title>
          <description>Participants received one of a variety of oral contraceptives or DMPA
DMPA: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
oral contraceptives: Oral contraceptives (any variety of formulations are permitted)</description>
        </group>
        <group group_id="B2">
          <title>Randomized LARC</title>
          <description>Participants receive one of the following interventions:
Implanon® or Nexplanon®; ParaGard®; Mirena®
Implanon®: Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
ParaGard®: Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
Mirena®: Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)</description>
        </group>
        <group group_id="B3">
          <title>Randomized SARC</title>
          <description>Participants received one of a variety of oral contraceptives or DMPA
DMPA: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
oral contraceptives: Oral contraceptives (any variety of formulations are permitted)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="522"/>
            <count group_id="B2" value="177"/>
            <count group_id="B3" value="195"/>
            <count group_id="B4" value="894"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" lower_limit="21" upper_limit="26"/>
                    <measurement group_id="B2" value="23" lower_limit="21" upper_limit="26"/>
                    <measurement group_id="B3" value="23" lower_limit="21" upper_limit="26"/>
                    <measurement group_id="B4" value="23" lower_limit="21" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="522"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="894"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Three participants did not provide race/ethnicity information</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic, white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="269"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic, black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All other single and multiple race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Contraceptive Method Discontinuation</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SARC - Preference</title>
            <description>Participants received one of a variety of oral contraceptives or DMPA
DMPA: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
oral contraceptives: Oral contraceptives (any variety of formulations are permitted)</description>
          </group>
          <group group_id="O2">
            <title>LARC - Randomized</title>
            <description>Participants receive one of the following interventions:
Implanon® or Nexplanon®; ParaGard®; Mirena®
Implanon®: Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
ParaGard®: Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
Mirena®: Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)</description>
          </group>
          <group group_id="O3">
            <title>SARC - Randomized</title>
            <description>Participants received one of a variety of oral contraceptives or DMPA
DMPA: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.</description>
          </group>
        </group_list>
        <measure>
          <title>Contraceptive Method Discontinuation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="177"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unintended Pregnancy</title>
        <description>Intent-to-treat principles applied.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SARC - Preference</title>
            <description>Participants received one of a variety of oral contraceptives or DMPA
DMPA: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
oral contraceptives: Oral contraceptives (any variety of formulations are permitted)</description>
          </group>
          <group group_id="O2">
            <title>LARC - Randomized</title>
            <description>Participants receive one of the following interventions:
Implanon® or Nexplanon®; ParaGard®; Mirena®
Implanon®: Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
ParaGard®: Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
Mirena®: Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)</description>
          </group>
          <group group_id="O3">
            <title>SARC - Randomized</title>
            <description>Participants received one of a variety of oral contraceptives or DMPA
DMPA: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.</description>
          </group>
        </group_list>
        <measure>
          <title>Unintended Pregnancy</title>
          <description>Intent-to-treat principles applied.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Attitudes to LARC vs SARC</title>
        <description>Level of happiness with initial method (% distribution)</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Preference SARC</title>
            <description>Participants received one of a variety of oral contraceptives or DMPA
DMPA: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
oral contraceptives: Oral contraceptives (any variety of formulations are permitted)</description>
          </group>
          <group group_id="O2">
            <title>Randomized LARC</title>
            <description>Participants receive one of the following interventions:
Implanon® or Nexplanon®; ParaGard®; Mirena®
Implanon®: Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
ParaGard®: Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
Mirena®: Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)</description>
          </group>
          <group group_id="O3">
            <title>Randomized SARC</title>
            <description>Participants received one of a variety of oral contraceptives or DMPA
DMPA: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
oral contraceptives: Oral contraceptives (any variety of formulations are permitted)</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Attitudes to LARC vs SARC</title>
          <description>Level of happiness with initial method (% distribution)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="177"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Happy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="354"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neutral</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unhappy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>Only serious adverse events were collected. AEs not captured.</desc>
      <group_list>
        <group group_id="E1">
          <title>SARC - Preference</title>
          <description>Participants received one of a variety of oral contraceptives or DMPA
DMPA: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
oral contraceptives: Oral contraceptives (any variety of formulations are permitted)</description>
        </group>
        <group group_id="E2">
          <title>LARC - Randomized</title>
          <description>Participants receive one of the following interventions:
Implanon® or Nexplanon®; ParaGard®; Mirena®
Implanon®: Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
ParaGard®: Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
Mirena®: Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)</description>
        </group>
        <group group_id="E3">
          <title>SARC - Randomized</title>
          <description>Participants received one of a variety of oral contraceptives or DMPA
DMPA: Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>endometritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Hubacher</name_or_title>
      <organization>FHI 360</organization>
      <phone>919 544 7040 ext 11223</phone>
      <email>dhubacher@fhi360.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

